SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 29, 2024	Mar. 31, 2024	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Mar. 18, 2025	Nov. 12, 2024	Nov. 01, 2024	Aug. 31, 2023
Subsequent Event [Line Items]
Preferred Stock, Conversion Basis					Subsequent to the period ended February 29, 2024, the Company entered into an Exchange Agreement with four investors whereas all of the Series B Preferred Stock, Series B-1 Preferred Stock, promissory notes and warrants issued by the Company to the investors, including all such securities currently held by the Investor representing approximately $16.1 million were exchanged for Series C-1 Preferred Stock of the Company totaling 14,250,000.
License Agreement Fee paid to NLC			$ 100,000		$ 100,000
Common Stock, Shares, Issued			22,470,239		22,470,239					20,470,239
Legal Fees			$ 35,300		$ 72,106	$ 20,500
Professional Fees			$ 105,366	$ 100,422	$ 170,123	$ 245,398
Financing capital raised	$ 1,500,000
Bonus to be paid	$ 100,000
Gross proceeds									$ 12,000
Gross proceeds								$ 600,000
Initial authorised shares							200,000,000
Increase in authorised shares							15,000,000,000
Preferred Series C Shares [Member]
Subsequent Event [Line Items]
Shares, Issued									1,200,000
Preferred Stock, Par or Stated Value Per Share									$ 0.001
Preferred Stock, Convertible, Conversion Price									$ 0.000000586216897634410
Security Sold Short, Shares									1,200,000
Preferred Series C One Shares [Member]
Subsequent Event [Line Items]
Shares, Issued									15,000,000
Preferred Stock, Par or Stated Value Per Share									$ 0.001
Preferred Stock, Convertible, Conversion Price									$ 0.00000209963072212
Conversion Of Stock Share Converted1								750,000
Preferred Series B1 Shares [Member]
Subsequent Event [Line Items]
Conversion Of Stock Share Converted1								14,250,000
Restricted Stock [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			1,023,511,950		1,023,511,950
Subsequent Event [Member]
Subsequent Event [Line Items]
Cash proceeds from debt		$ 300,000
Purchase price of warrants		$ 0.08
Common shares issued at $0.225, shares		14,117,646
Malpractice Loss Contingency, Discount Rate		15.00%
Subordinated Borrowing, Interest Rate		8.00%
Conversion price		$ 0.025
Conversion price		$ 0.025
Subsequent Event, Description	the following royalties, if any to NLC: (1) In respect of sales of Nutra: 12.0% on the first $2.5 million in net sales generated from the sale of Nutra, 9.0% on the next $2.5 million in net sales generated from the sale of Nutra and 6% of net sales generated from the sale of Nutra thereafter; and (2) In respect of sales of NLC001: 12.0% on the first $2.5 million in net sales generated from the sale of NLC001, 9.0% on the next $2.5 million in net sales generated from the sale of NLC001 and 6% of net sales generated from the sale of NLC001 thereafter. Commencing on the second anniversary of the closing of the license agreement and for the remainder of the term of the license agreement, the Company shall also be entitled to a minimum payment of $25,000 per quarter.
Professional Fees	$ 12,500

Innovation1 Biotech Inc. 10-Q